FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold On Shares Of Solventum Corporation

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our 12-month price target by $6 to $76, reflecting an 11.6x multiple of our 2026 EPS estimate, in line with the 11.6x historical forward average since spin-off from 3M in 2024. We raise our 2026 EPS estimate to $6.57 from $6.46 and lower our 2027 estimate by $0.03 to $7.03. We think SOLV continues to demonstrate progress with the separation from 3M, having exited over 50% of the transition service agreements with a target to exit over 90% by year-end. In addition, over 75% of system applications have been migrated, according to Q1 earnings commentary. The company maintained the $100M-$120M estimate of tariff headwinds against 2026 earnings. However, this estimate was made based on tariff dynamics prior to the U.S. Supreme Court's recent ruling against the IIEPA tariffs, adding some uncertainty to SOLV's near-term financial outlook, in our view, as the company awaits more information about potential refund dynamics.

Related Articles

Australia

Open Text Q1 Total Revenues of US$1.28

Price: $32.53, Change: $+1.12, Percent Change: +3.57%

$OTEX.TO
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of Qiagen

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target price of USD36, implying a 2026 P/E of 14.7x. This is at a discount to its historical average (20x-22x) to reflect the headwinds on its key growth contributor QuantiFERON, along with increased geopolitical and management uncertainties. This is partly cushioned by growth opportunities from other key products and improving shareholder returns. Qiagen published its full Q1 2026 results, which were in line with the preliminary results released in April. Q1 2026 net sales fell 1% CER dragged by QuantiFERON sales declining 5% CER due to reduced immigration testing demand in the U.S. and Middle East. In April, Qiagen downgraded 2026 guidance to 1%-2% CER sales growth from at least 5% and adjusted EPS to at least USD2.43 CER from USD2.50, and expect stronger trends in H2 supported by acquisition benefits and sequential QuantiFERON improvement. Our EPS estimates remained unchanged given the full Q1 results were in line with the preliminary figures.

$QGEN
Commodities

Weekly RIN Values Trade Higher, EcoEngineers Says

The Renewable Identification Numbers weekly markets traded higher for the week of April 29 to May 6, according to EcoEngineers Carbon Market Snapshot.Current year D4 2026 biomass-based diesel RIN prices were trading at $2.07 per RIN on Thursday, up from $1.96/RIN a week ago.D5 2026 advanced biofuel RINs were trading around $2.06/RIN, compared with $1.95/RIN a week ago.D6 2026 corn-based ethanol RIN prices finished trading on Thursday at $2.02/RIN, above $1.92/RIN a week ago.